Definium Therapeutics, Inc.

NASDAQ:DFTX

Biotechnology

Healthcare
$29.12 -1.67%

-$0.41 today

Market cap
$3.99B
Beta
2.38
P/E (TTM)
-11.0
EPS (TTM)
-$2.18
52W Low $12.88High $26.15

Volume 1.91M

Average 2.67M

DFTX Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Definium Therapeutics, Inc.NASDAQ: DFTX

Weighted Avg Shares · Q3 FY2026 · quarter ended Sep 2026

Weighted avg shares growth accelerates

Q3 FY2026 weighted avg shares of 135.94M shares rose 58.3% year over year, ahead of the +30.7% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 22.8% from the prior quarter. Over 3 fiscal years it compounded at +42.5% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +58.3% holds above the trailing-twelve-month pace of +30.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
135.94M+22.8% QoQ
Last fiscal yearDec 2025
89.33M+26.8% YoY
LTMSep 2026
111.19M+30.7% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+58.3%——
1 year+26.8%——
3-year CAGR+42.5%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
89.33M USD
Year-over-year change
+26.8%
4-year CAGR
+34.4%

Weighted Avg Shares vs competitors

How DFTX compares with its peers on the latest reported figures

  • DFTX's LTM Sep 2026 weighted avg shares of 111.19M shares is the 2nd highest of the 11 companies compared; the peer median is 35.82M shares.
  • Its year-over-year change of +30.7% is the 4th highest of 10, against a peer median of +15.9%.
  • Over three fiscal years its annual growth of +42.5% compares with a peer median of +11.8%.
DFTX Competitors Peer median
Weighted Avg Shares for DFTX and competitors
Company Period LTM YoY 3-year CAGR
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026166.7M +4.0%+2.4%
DFTXDefinium Therapeutics, Inc.LTM Sep 2026111.19M +30.7%+42.5%
GHRSGH Research PLCLTM Mar 202662.03M +15.9%+5.5%
AXSMAxsome Therapeutics, Inc.LTM Jun 202650.84M +4.3%+7.0%
MPLTMapLight Therapeutics, Inc.LTM Mar 202643.04M +3.9%+2.0%
RAPPRapport Therapeutics, Inc. Common StockLTM Mar 202641.9M +115.2%+32.7%
ANROAlto Neuroscience, Inc.LTM Mar 202629.75M +10.2%+4.1%
PRAXPraxis Precision Medicines, Inc.LTM Sep 202627.42M +29.8%+94.2%
NERVMinerva Neurosciences, Inc.LTM Jun 202627.3M +260.6%+16.6%
LBRXLB Pharmaceuticals Inc Common StockLTM Mar 202619.77M —+92.6%
ATHEAlterity Therapeutics LimitedFY202510.66M +75.3%+38.5%
Peer median (excluding DFTX) 35.82M+15.9%+11.8%

Competitors are the stored peer set for DFTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue003.16M527K0
Gross Profit00(3.16M)(527K)0
Gross Margin—————
Research & Development34.79M36.17M48.96M65.3M117.67M
Selling, General & Admin59.07M30.16M41.74M38.62M48.64M
Operating Expenses93.85M66.33M90.7M103.39M166.31M
Depreciation & Amortization2.62M3.18M3.16M527K0
EBITDA(91.22M)(52.12M)(92.57M)(105.87M)(178.31M)
EBITDA Margin—————
Operating Income(93.85M)(66.33M)(93.87M)(103.92M)(166.31M)
Operating Margin—————
Interest Income01.5M5.58M11.56M10.96M
Interest Expense359K1.5M920K2.28M5.48M
Other Income / Expenses(339K)9.54M(1.87M)(4.76M)(17.48M)
Income Before Tax(94.19M)(56.8M)(95.73M)(108.68M)(183.79M)
Pre-Tax Margin—————
Income Tax Expense(1.16M)0000
Net Income(93.04M)(56.8M)(95.73M)(108.68M)(183.79M)
Net Margin—————
EPS (Basic)(3.40)(1.53)(2.44)(1.54)(2.06)
EPS (Diluted)(3.40)(1.53)(2.44)(0.15)(2.06)
Weighted Avg Shares27.38M30.86M39.16M70.46M89.33M
Weighted Avg Shares (Diluted)27.38M30.86M39.16M704.61M89.33M

Definium Therapeutics, Inc.

NASDAQ:DFTX

Intrinsic Alpha fair value

Locked

Current Price

$29.12

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.